FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4221081837> ?p ?o ?g. }

• W4221081837 endingPage "447" @default.
• W4221081837 startingPage "440" @default.
• W4221081837 abstract "Objective: The aim of this study was to examine the clinical efficacy and safety of the duodenal-jejunal bypass liner (DJBL) while in situ for 12 months and for 12 months after explantation. Summary Background Data: This is the largest randomized controlled trial (RCT) of the DJBL, a medical device used for the treatment of people with type 2 diabetes mellitus (T2DM) and obesity. Endoscopic interventions have been developed as potential alternatives to those not eligible or fearful of the risks of metabolic surgery. Methods: In this multicenter open-label RCT, 170 adults with inadequately controlled T2DM and obesity were randomized to intensive medical care with or without the DJBL. Primary outcome was the percentage of participants achieving a glycated hemoglobin reduction of ≥20% at 12 months. Secondary outcomes included weight loss and cardiometabolic risk factors at 12 and 24 months. Results: There were no significant differences in the percentage of patients achieving the primary outcome between both groups at 12 months [DJBL 54.6% (n = 30) vs control 55.2% (n = 32); odds ratio (OR) 0.93, 95% confidence interval (CI): 0.44–2.0; P = 0.85]. Twenty-four percent (n = 16) patients achieved ≥15% weight loss in the DJBL group compared to 4% (n = 2) in the controls at 12 months (OR 8.3, 95% CI: 1.8–39; P = .007). The DJBL group experienced superior reductions in systolic blood pressure, serum cholesterol, and alanine transaminase at 12 months. There were more adverse events in the DJBL group. Conclusions: The addition of the DJBL to intensive medical care was associated with superior weight loss, improvements in cardiometabolic risk factors, and fatty liver disease markers, but not glycemia, only while the device was in situ. The benefits of the devices need to be balanced against the higher rate of adverse events when making clinical decisions. Trial Registration: ISRCTN30845205. isrctn.org; Efficacy and Mechanism Evaluation Programme, a Medical Research Council and National Institute for Health Research (NIHR) partnership reference 12/10/04." @default.
• W4221081837 created "2022-04-03" @default.
• W4221081837 creator A5000149363 @default.
• W4221081837 creator A5001255955 @default.
• W4221081837 creator A5004085589 @default.
• W4221081837 creator A5005770101 @default.
• W4221081837 creator A5005982279 @default.
• W4221081837 creator A5009451273 @default.
• W4221081837 creator A5009661570 @default.
• W4221081837 creator A5010453338 @default.
• W4221081837 creator A5012389412 @default.
• W4221081837 creator A5017550082 @default.
• W4221081837 creator A5027474816 @default.
• W4221081837 creator A5027773961 @default.
• W4221081837 creator A5032089820 @default.
• W4221081837 creator A5034439951 @default.
• W4221081837 creator A5045917020 @default.
• W4221081837 creator A5049567229 @default.
• W4221081837 creator A5053346837 @default.
• W4221081837 creator A5053661969 @default.
• W4221081837 creator A5053747302 @default.
• W4221081837 creator A5056332857 @default.
• W4221081837 creator A5058406872 @default.
• W4221081837 creator A5064381125 @default.
• W4221081837 creator A5065474321 @default.
• W4221081837 creator A5078574509 @default.
• W4221081837 creator A5082811599 @default.
• W4221081837 creator A5086682844 @default.
• W4221081837 creator A5086971280 @default.
• W4221081837 creator A5091060967 @default.
• W4221081837 creator A5091534696 @default.
• W4221081837 date "2021-06-15" @default.
• W4221081837 modified "2023-10-06" @default.
• W4221081837 title "Duodenal-Jejunal Bypass Liner for the management of Type 2 Diabetes Mellitus and Obesity" @default.
• W4221081837 cites W2078611185 @default.
• W4221081837 cites W2148293498 @default.
• W4221081837 cites W2170005843 @default.
• W4221081837 cites W2172193326 @default.
• W4221081837 cites W2292946576 @default.
• W4221081837 cites W2548192404 @default.
• W4221081837 cites W2595706111 @default.
• W4221081837 cites W2761365156 @default.
• W4221081837 cites W2791382640 @default.
• W4221081837 cites W2800870406 @default.
• W4221081837 cites W2915948028 @default.
• W4221081837 cites W4230723816 @default.
• W4221081837 doi "https://doi.org/10.1097/sla.0000000000004980" @default.
• W4221081837 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34647708" @default.
• W4221081837 hasPublicationYear "2021" @default.
• W4221081837 type Work @default.
• W4221081837 citedByCount "12" @default.
• W4221081837 countsByYear W42210818372021 @default.
• W4221081837 countsByYear W42210818372022 @default.
• W4221081837 countsByYear W42210818372023 @default.
• W4221081837 crossrefType "journal-article" @default.
• W4221081837 hasAuthorship W4221081837A5000149363 @default.
• W4221081837 hasAuthorship W4221081837A5001255955 @default.
• W4221081837 hasAuthorship W4221081837A5004085589 @default.
• W4221081837 hasAuthorship W4221081837A5005770101 @default.
• W4221081837 hasAuthorship W4221081837A5005982279 @default.
• W4221081837 hasAuthorship W4221081837A5009451273 @default.
• W4221081837 hasAuthorship W4221081837A5009661570 @default.
• W4221081837 hasAuthorship W4221081837A5010453338 @default.
• W4221081837 hasAuthorship W4221081837A5012389412 @default.
• W4221081837 hasAuthorship W4221081837A5017550082 @default.
• W4221081837 hasAuthorship W4221081837A5027474816 @default.
• W4221081837 hasAuthorship W4221081837A5027773961 @default.
• W4221081837 hasAuthorship W4221081837A5032089820 @default.
• W4221081837 hasAuthorship W4221081837A5034439951 @default.
• W4221081837 hasAuthorship W4221081837A5045917020 @default.
• W4221081837 hasAuthorship W4221081837A5049567229 @default.
• W4221081837 hasAuthorship W4221081837A5053346837 @default.
• W4221081837 hasAuthorship W4221081837A5053661969 @default.
• W4221081837 hasAuthorship W4221081837A5053747302 @default.
• W4221081837 hasAuthorship W4221081837A5056332857 @default.
• W4221081837 hasAuthorship W4221081837A5058406872 @default.
• W4221081837 hasAuthorship W4221081837A5064381125 @default.
• W4221081837 hasAuthorship W4221081837A5065474321 @default.
• W4221081837 hasAuthorship W4221081837A5078574509 @default.
• W4221081837 hasAuthorship W4221081837A5082811599 @default.
• W4221081837 hasAuthorship W4221081837A5086682844 @default.
• W4221081837 hasAuthorship W4221081837A5086971280 @default.
• W4221081837 hasAuthorship W4221081837A5091060967 @default.
• W4221081837 hasAuthorship W4221081837A5091534696 @default.
• W4221081837 hasBestOaLocation W42210818371 @default.
• W4221081837 hasConcept C126322002 @default.
• W4221081837 hasConcept C134018914 @default.
• W4221081837 hasConcept C141071460 @default.
• W4221081837 hasConcept C156957248 @default.
• W4221081837 hasConcept C168563851 @default.
• W4221081837 hasConcept C197934379 @default.
• W4221081837 hasConcept C203092338 @default.
• W4221081837 hasConcept C2777180221 @default.
• W4221081837 hasConcept C2777538456 @default.
• W4221081837 hasConcept C2910068830 @default.
• W4221081837 hasConcept C44249647 @default.
• W4221081837 hasConcept C511355011 @default.
• W4221081837 hasConcept C544821477 @default.

• next